570 related articles for article (PubMed ID: 17007735)
21. Advances in huntington disease drug discovery: novel approaches to model disease phenotypes.
Bard J; Wall MD; Lazari O; Arjomand J; Munoz-Sanjuan I
J Biomol Screen; 2014 Feb; 19(2):191-204. PubMed ID: 24196395
[TBL] [Abstract][Full Text] [Related]
22. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
23. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
Mangiarini L; Sathasivam K; Seller M; Cozens B; Harper A; Hetherington C; Lawton M; Trottier Y; Lehrach H; Davies SW; Bates GP
Cell; 1996 Nov; 87(3):493-506. PubMed ID: 8898202
[TBL] [Abstract][Full Text] [Related]
24. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.
Southwell AL; Ko J; Patterson PH
J Neurosci; 2009 Oct; 29(43):13589-602. PubMed ID: 19864571
[TBL] [Abstract][Full Text] [Related]
25. Huntington's disease: From molecular basis to therapeutic advances.
Krobitsch S; Kazantsev AG
Int J Biochem Cell Biol; 2011 Jan; 43(1):20-4. PubMed ID: 21056115
[TBL] [Abstract][Full Text] [Related]
26. Dysfunctional Dopaminergic Neurones in Mouse Models of Huntington's Disease: A Role for SK3 Channels.
Dallérac GM; Levasseur G; Vatsavayai SC; Milnerwood AJ; Cummings DM; Kraev I; Huetz C; Evans KA; Walters SW; Rezaie P; Cho Y; Hirst MC; Murphy KP
Neurodegener Dis; 2015; 15(2):93-108. PubMed ID: 25871323
[TBL] [Abstract][Full Text] [Related]
27. Huntington's disease: from molecular pathogenesis to clinical treatment.
Ross CA; Tabrizi SJ
Lancet Neurol; 2011 Jan; 10(1):83-98. PubMed ID: 21163446
[TBL] [Abstract][Full Text] [Related]
28. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.
Harper SQ; Staber PD; He X; Eliason SL; Martins IH; Mao Q; Yang L; Kotin RM; Paulson HL; Davidson BL
Proc Natl Acad Sci U S A; 2005 Apr; 102(16):5820-5. PubMed ID: 15811941
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.
Rising AC; Xu J; Carlson A; Napoli VV; Denovan-Wright EM; Mandel RJ
Exp Neurol; 2011 Apr; 228(2):173-82. PubMed ID: 21192926
[TBL] [Abstract][Full Text] [Related]
30. Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset.
Vatsavayai SC; Dallérac GM; Milnerwood AJ; Cummings DM; Rezaie P; Murphy KP; Hirst MC
Brain Res Bull; 2007 Apr; 72(2-3):98-102. PubMed ID: 17352932
[TBL] [Abstract][Full Text] [Related]
31. Viral-mediated overexpression of mutant huntingtin to model HD in various species.
Ruiz M; Déglon N
Neurobiol Dis; 2012 Nov; 48(2):202-11. PubMed ID: 21889981
[TBL] [Abstract][Full Text] [Related]
32. Is There Convincing Evidence that Intermediate Repeats in the HTT Gene Cause Huntington's Disease?
Oosterloo M; Van Belzen MJ; Bijlsma EK; Roos RA
J Huntingtons Dis; 2015; 4(2):141-8. PubMed ID: 26397895
[TBL] [Abstract][Full Text] [Related]
33. Mouse models of Huntington's disease and methodological considerations for therapeutic trials.
Ferrante RJ
Biochim Biophys Acta; 2009 Jun; 1792(6):506-20. PubMed ID: 19362590
[TBL] [Abstract][Full Text] [Related]
34. Pathogenic cellular phenotypes are germline transmissible in a transgenic primate model of Huntington's disease.
Putkhao K; Kocerha J; Cho IK; Yang J; Parnpai R; Chan AW
Stem Cells Dev; 2013 Apr; 22(8):1198-205. PubMed ID: 23190281
[TBL] [Abstract][Full Text] [Related]
35. Mutant huntingtin can paradoxically protect neurons from death.
Zuchner T; Brundin P
Cell Death Differ; 2008 Mar; 15(3):435-42. PubMed ID: 17975550
[TBL] [Abstract][Full Text] [Related]
36. [Huntington's disease: clinical and molecular genetics].
Warita H; Shiro Y; Kashihara K; Abe K
Nihon Rinsho; 1999 Apr; 57(4):896-9. PubMed ID: 10222786
[TBL] [Abstract][Full Text] [Related]
37. Murine Models of Huntington's Disease for Evaluating Therapeutics.
Kosior N; Leavitt BR
Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
[TBL] [Abstract][Full Text] [Related]
38. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients.
Sathasivam K; Woodman B; Mahal A; Bertaux F; Wanker EE; Shima DT; Bates GP
Hum Mol Genet; 2001 Oct; 10(21):2425-35. PubMed ID: 11689489
[TBL] [Abstract][Full Text] [Related]
39. Huntington's disease.
MacDonald ME; Gines S; Gusella JF; Wheeler VC
Neuromolecular Med; 2003; 4(1-2):7-20. PubMed ID: 14528049
[TBL] [Abstract][Full Text] [Related]
40. Neurobiology of Huntington's Disease.
De Souza RA; Leavitt BR
Curr Top Behav Neurosci; 2015; 22():81-100. PubMed ID: 25205327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
